Amiloride analogues substituted on the cyclic guanidine moiety as ENaC blockers for treating respiratory diseases
申请人:Novartis AG
公开号:EP2520574A1
公开(公告)日:2012-11-07
A compound of Formula I
in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. In particular, airway diseases like COPD and cystic fibrosis are treatable, but also inflammatory and allergic diseases.
Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
式 I 的化合物
其中 R1、R2、R3、R4、R5、R6、R7、R8、R9、R10 和 R11 的含义如说明书所示,可用于治疗对阻断上皮钠通道有反应的疾病。特别是,可治疗慢性阻塞性肺病和囊性纤维化等气道疾病,也可治疗炎症性和过敏性疾病。
此外,还描述了含有该化合物的药物组合物以及制备该化合物的工艺。